Q-omics provides the consensus-scored CCDC24 profile across patient tissues and cancer cell-line models. CCDC24 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CCDC24 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CCDC24 RNA expression shows 17,647 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KICH, and ACC as cancer lineages where CCDC24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC24 survival associations across molecular data types. CCDC24 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC24 RNA expression–survival associations across cancer types. High CCDC24 expression shows unfavorable associations in KIRC, LIHC and ACC, but favorable associations in BRCA, HNSC and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CCDC24 RNA expression.
This table summarizes CCDC24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC24 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LIHC, STAD and LUAD. The KICH box plot shows higher CCDC24 RNA expression in normal versus tumor tissue (log2 FC = −1.693, t-test p < 0.001).
This table shows molecular features associated with CCDC24 in patient tissues and cancer cell lines. In patient samples, CCDC24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
